25‐hydroxyvitamin D sufficiency is associated with lower de novo anti‐HLA donor specific antibody and better kidney transplant outcomes

Abstract

T‐cell mediated rejection (TCMR), de novo anti‐HLA donor‐specific antibodies (dnDSAs) and ensuing antibody‐mediated rejection (ABMR) reduce kidney transplantation (KT) survival. The immunomodulatory effects of 25‐hydroxyvitamin D [25(OH)D] could be beneficial for KT outcomes. We aimed to evaluating the association between 25(OH)D levels, the development of dnDSAs, clinical TCMR and ABMR, and graft survival. This single center retrospective study included 253 KT recipients (KTRs) transplanted without preformed DSA between 2010 and 2013. We measured 25(OH)D in successive serum samples: at KT (M0) and M12 for the entire cohort, and additionally at M24 and/or M36 when sera were available. We assessed graft outcomes up to 5 years post‐KT. The proportion of KTRs having sufficient 25(OH)D at KT (M0) was high (81.4%) and then dropped at M12 (71.1%). KTRs with sufficient 25(OH)D at M0 experienced less clinical TCMR (HR, 0.41; 95% CI, 0.19–0.88 in multivariate analysis). A sufficient 25(OH)D at M12 was independently associated with a longer dnDSA‐free survival (HR, 0.34; 95% CI, 0.17–0.69). There was no association between 25(OH)D and clinical AMBR. Studying the KTRs with 25(OH)D measurements at M12, M24 and M36 (n = 203), we showed that 25(OH)D sufficiency over the 3 first‐years post‐KT was associated with a longer graft survival in multivariate analyses (HR, 0.39; 95% CI, 0.22–0.70). To our knowledge, this study is the first showing an association between 25(OH)D sufficiency post‐KT and dnDSA occurrence in KTRs. Moreover, we reinforce previously published data showing an association between 25(OH)D, TCMR and graft survival in KT.